The Latest Cardiac and Vascular News
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leading AI-driven health technology company, today announced a collaboration with AliveCor to develop Anumana’s advanced AI algorithms for early cardiac disease detection on AliveCor’s Kardia electrocardiogram (ECG) devices, starting with Anumana’s FDA-cleared algorithm, ECG-AI™ LEF. “This collaboration demonstrates Anumana’s commitment to harnessing the potential of AI to expand […]
DUBLIN–(BUSINESS WIRE)–FIRE1, a leading connected medical device solutions company, today announced the successful completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. “From the beginning, our team has been driven by two core goals: creating […]
January 07, 2025 07:30 AM Eastern Standard Time KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, Inc., (“XyloCor”), a clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of a $67.5 million Series B financing. New investment will support a randomized, double-blind Phase 2b clinical trial […]
January 07, 2025 07:05 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–AccurKardia, an innovator in ECG-based diagnostics technology, has announced that it has received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its ECG-based, AI-powered AK+ Guard™ hyperkalemia detection software. The investigational technology uses Lead I ECG data […]
CAMPBELL, Calif.–(BUSINESS WIRE)–Simpson Interventions, Inc., a pioneering medical technology company, specializing in cardiovascular interventional devices, today announced achievement of major development milestones. Its truly unique Acolyte™ Image-Guided Crossing and Re-Entry Catheter System has been granted an Investigational Device Exemption by the U.S. Food and Drug Administration (FDA), after having been […]
AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical, Inc., a privately held medical device company pioneering a no-implant atrial shunt for heart failure, today announced two significant milestones from the U.S. Food and Drug Administration (FDA). The FDA has granted the company investigational device exemption (IDE) approval to begin a pivotal trial focused on […]
SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc., a medical technology startup backed by Vensana Capital® developing an AI-powered next-generation intravascular ultrasound (IVUS) platform, is pleased to announce the appointment of Scott R. Ward to its Board of Directors. “We are thrilled to welcome Scott to the Evident Vascular Board” Post this […]
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the publication of a detailed review of its collaboration with U.S.-based Minnetronix, a world leader in high-precision medical device manufacturing. Published in the industry journal, Medical Design & Development, the article was co-authored by Tom Looby, Conavi Medical’s CEO and Darcy Hart, Minnetronix Medical’s Director of Optical Products.
Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari’s innovative product portfolio is highly complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Medtronic plc, a global leader in healthcare technology, today announced it received CE (Conformité Européenne) Mark for the Harmony™ Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT). The Harmony TPV system […]
